Data from: Expression profiling of human pluripotent stem cell-derived cardiomyocytes exposed to doxorubicin—integration and visualization of multi-omics data

Anthracyclines, such as doxorubicin, are highly efficient chemotherapeutic
agents against a variety of cancers. However, anthracyclines are also
among the most cardiotoxic therapeutic drugs presently on the market.
Chemotherapeutic-induced cardiomyopathy is one of the leading causes of
disease and mortality in cancer survivors. The exact mechanisms
responsible for doxorubicin-induced cardiomyopathy are not completely
known, but the fact that the cardiotoxicity is dose-dependent and that
there is a variation in time-to-onset of toxicity, and gender- and age
differences suggests that several mechanisms may be involved. In this
study, we investigated doxorubicin-induced cardiotoxicity in human
pluripotent stem cell-derived cardiomyocytes using proteomics. In
addition, different sources of omics data (protein, mRNA, and microRNA)
from the same experimental setup were further combined and analyzed using
newly developed methods to identify differential expression in data of
various origin and types. Subsequently, the results were integrated in
order to generate a combined visualization of the findings. In our
experimental model system, we exposed cardiomyocytes derived from human
pluripotent stem cells to doxorubicin for up to 2 days, followed by a
wash-out period of additionally 12 days. Besides an effect on the cell
morphology and cardiomyocyte functionality, the data show a strong effect
of doxorubicin on all molecular levels investigated. Differential
expression patterns that show a linkage between the proteome,
transcriptome, and the regulatory microRNA network, were identified. These
findings help to increase the understanding of the mechanisms behind
anthracycline-induced cardiotoxicity and suggest putative biomarkers for
this condition.